207 related articles for article (PubMed ID: 34573422)
41. Lack of somatic alterations of MC1R in primary melanoma.
Kim RD; Curtin JA; Bastian BC
Pigment Cell Melanoma Res; 2008 Oct; 21(5):579-82. PubMed ID: 18761657
[TBL] [Abstract][Full Text] [Related]
42. Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients.
Pellegrini C; Raimondi S; Di Nardo L; Ghiorzo P; Menin C; Manganoni MA; Palmieri G; Guida G; Quaglino P; Stanganelli I; Massi D; Pastorino L; Elefanti L; Tosti G; Queirolo P; Leva A; Maurichi A; Rodolfo M; Fargnoli MC;
J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):213-221. PubMed ID: 34664323
[TBL] [Abstract][Full Text] [Related]
43. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
[TBL] [Abstract][Full Text] [Related]
44. MC1R germline variants confer risk for BRAF-mutant melanoma.
Landi MT; Bauer J; Pfeiffer RM; Elder DE; Hulley B; Minghetti P; Calista D; Kanetsky PA; Pinkel D; Bastian BC
Science; 2006 Jul; 313(5786):521-2. PubMed ID: 16809487
[TBL] [Abstract][Full Text] [Related]
45. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
46. A germline oncogenic MITF mutation and tumor susceptibility.
Paillerets BB; Lesueur F; Bertolotto C
Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
[TBL] [Abstract][Full Text] [Related]
47. Germline mutations predisposing to melanoma.
Toussi A; Mans N; Welborn J; Kiuru M
J Cutan Pathol; 2020 Jul; 47(7):606-616. PubMed ID: 32249949
[TBL] [Abstract][Full Text] [Related]
48. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
50. Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Bianchi Scarrà G; Hayward NK; Hansson J
J Invest Dermatol; 2010 Feb; 130(2):618-20. PubMed ID: 19759551
[No Abstract] [Full Text] [Related]
51. Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications.
Pollio A; Tomasi A; Pellacani G; Ruini C; Mandel VD; Fortuna G; Seidenari S; Ponti G
Melanoma Res; 2014 Jun; 24(3):267-72. PubMed ID: 24638154
[TBL] [Abstract][Full Text] [Related]
52. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
53. MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors.
Berwick M; MacArthur J; Orlow I; Kanetsky P; Begg CB; Luo L; Reiner A; Sharma A; Armstrong BK; Kricker A; Cust AE; Marrett LD; Gruber SB; Anton-Culver H; Zanetti R; Rosso S; Gallagher RP; Dwyer T; Venn A; Busam K; From L; White K; Thomas NE;
Pigment Cell Melanoma Res; 2014 May; 27(3):485-8. PubMed ID: 24406078
[TBL] [Abstract][Full Text] [Related]
54. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
[TBL] [Abstract][Full Text] [Related]
55. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
[TBL] [Abstract][Full Text] [Related]
56. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
Puig-Butille JA; Escámez MJ; Garcia-Garcia F; Tell-Marti G; Fabra À; Martínez-Santamaría L; Badenas C; Aguilera P; Pevida M; Dopazo J; del Río M; Puig S
Oncotarget; 2014 Mar; 5(6):1439-51. PubMed ID: 24742402
[TBL] [Abstract][Full Text] [Related]
57. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers.
Gironi LC; Colombo E; Pasini B; Giorgione R; Farinelli P; Zottarelli F; Esposto E; Zavattaro E; Allara E; Ogliara P; Betti M; Dianzani I; Savoia P
Arch Dermatol Res; 2018 Dec; 310(10):769-784. PubMed ID: 30218143
[TBL] [Abstract][Full Text] [Related]
58. MC1R variants increase risk of melanomas harboring BRAF mutations.
Fargnoli MC; Pike K; Pfeiffer RM; Tsang S; Rozenblum E; Munroe DJ; Golubeva Y; Calista D; Seidenari S; Massi D; Carli P; Bauer J; Elder DE; Bastian BC; Peris K; Landi MT
J Invest Dermatol; 2008 Oct; 128(10):2485-90. PubMed ID: 18368129
[TBL] [Abstract][Full Text] [Related]
59. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.
Conway C; Beswick S; Elliott F; Chang YM; Randerson-Moor J; Harland M; Affleck P; Marsden J; Sanders DS; Boon A; Knowles MA; Bishop DT; Newton-Bishop JA
Genes Chromosomes Cancer; 2010 May; 49(5):425-38. PubMed ID: 20140953
[TBL] [Abstract][Full Text] [Related]
60. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
